Efficacy of chemotherapy combined with sorafenib for FLT3-ITD-positive acute myeloid leukemia
10.3760/cma.j.cn341190-20220121-00063
- VernacularTitle:化疗联合索拉非尼治疗FLT3-ITD阳性AML的疗效研究
- Author:
Xuemei WANG
1
;
Zhengpeng YANG
;
Heng GUO
;
Tianjiao HUANG
;
Jinfeng LI
;
Bo AN
;
Xue YANG
;
Hong ZHOU
Author Information
1. 齐齐哈尔医学院附属第二医院血液科，齐齐哈尔 161000
- Keywords:
Leukemia,myeloid,acute;
fms-Like tyrosine kinase 3;
Genes,suppressor;
Tandem repeat sequences;
Drug therapy,combination;
Antineoplastic combined chemothera
- From:
Chinese Journal of Primary Medicine and Pharmacy
2022;29(12):1807-1812
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the effect of chemotherapy combined with sorafenib on the prognosis of FLT3 internal tandem duplication (FLT3-ITD)-positive acute myeloid leukemia and to find a more effective treatment.Methods:The clinical data of 60 patients who were newly diagnosed with acute myeloid leukemia and who received treatment in The Second Affiliated Hospital of Qiqihar Medical University from January 2015 to January 2017 were retrospectively analyzed. The patients were divided into three groups according to whether they were positive for FLT3-ITD and the treatment method they used. The observation group (FLT3-ITD-positive, n = 19) were treated with sorafenib based on routine chemotherapy. The control group 1 (FLT3-ITD-positive, n = 21) was treated only with routine chemotherapy. The control group 2 (FLT3-ITD-negative, n = 20) was treated only with routine chemotherapy. After the first and fourth courses of treatment, clinical efficacy was compared among the three groups. Results:After the first course of treatment, the complete remission rate in control group 2 was 50.0% (10/20), which was significantly higher than 15.8% (3/19) in the observation group and 4.8% (1/21) in the control group 1 ( H = 13.39, P < 0.05). After the fourth course of treatment, the complete remission rate in the observation group, control group 2, and control group 1 was 63.2% (12/19), 60.0% (12/20), and 4.8% (1/21), respectively, and the differences were statistically significant ( H = 19.21, P < 0.05). Four-year follow-up results showed that the median survival time in the observation group, control group 1, and control group 2 was 36.63, 24.15, and 45.00 months respectively. The event-free survival in the observation group, control group 1, and control group 2 was 18.00, 9.82, and 24.90 months, respectively. The median survival time and the event-free survival in the control group 2 were significantly longer than those in the observation group and control group 1 ( χ2 = 19.93, 23.04, both P < 0.001). Conclusion:Chemotherapy combined with sorafenib for treating newly-diagnosed FLT3-ITD-positive acute myeloid leukemia can provide comprehensive benefits and have advantages for survival over chemotherapy without sorafenib and chemotherapy alone.
